GET DAILY SIGNALSCelldex Therapeutics (CLDX) Q3 2026: Phase 3 Data Overshadows the Quarterly Loss
Key Takeaways
- Celldex reported a third quarter 2026 GAAP net loss of $0.96 per share, beating the consensus estimate of approximately -$1.02 by about $0.07.
- Revenue remained minimal, reflecting the company's status as a clinical-stage biotech with no approved products on the market.
- The quarter's centerpiece was clinical, not financial: positive Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 results for barzolvolimab in chronic spontaneous urticaria (CSU), a chronic hives condition.
- Management reiterated plans to submit a Biologics License Application (BLA) — a request for regulatory approval to market a biologic drug — for barzolvolimab in CSU, anticipated in 2027.
- Net losses widened year-over-year as research and development (R&D) spending ramped to support late-stage clinical programs.
- Investor attention remains fixed on clinical readouts and the regulatory timeline rather than near-term profitability.
Why the Quarter Matters More for the Pipeline Than the Numbers
Celldex Therapeutics is a clinical-stage biotechnology company focused on antibody-based therapies for inflammatory, allergic, and autoimmune diseases. With no approved products yet, its quarterly financials take a back seat to progress in the pipeline. The lead candidate, barzolvolimab, targets mast cells and is being developed for chronic spontaneous urticaria along with related conditions. Positive late-stage results from this quarter have raised the profile of the program ahead of a planned regulatory filing. In my view, the third quarter 2026 report served mainly as a checkpoint on cash position, R&D discipline, and the strength of the supporting data for what could become the company's first commercial product.
What the Reported Results Showed
For the third quarter of 2026, Celldex posted a GAAP net loss of $0.96 per share, which came in narrower than the consensus estimate of roughly -$1.02. Revenue stayed negligible, as expected for a pre-commercial company whose limited income stems from grants and collaboration agreements rather than product sales. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The more meaningful updates were operational. The company released positive results from the Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies, highlighting rapid, profound, and sustained efficacy for barzolvolimab in chronic spontaneous urticaria. Management repeated its plan to submit a BLA for barzolvolimab in CSU during 2027. At the same time, R&D expenses rose to advance both late-stage and earlier programs, which contributed to a wider net loss compared with the prior year. A Phase 3 study of barzolvolimab in cold urticaria continues as well.
How Investors Reacted to the Update
Market focus stayed on the barzolvolimab data rather than the bottom-line loss. Because Celldex remains pre-revenue, investors tend to look past the quarterly net loss and instead assess the strength of the Phase 3 CSU findings, the expected 2027 BLA filing, and the cash position. Analyst commentary after the release has stayed constructive, with several firms keeping favorable ratings and price targets comfortably above recent trading levels. That said, risk remains part of the picture: clinical-stage biotechs can swing sharply around regulatory events, and any delay in the filing timeline or new data concerns could alter positioning quickly.
What to Watch in the Months Ahead
The next twelve months will likely center on regulatory execution. Investors should track further details around the planned BLA submission for barzolvolimab in CSU, including any additional data packages or manufacturing updates the company may share. Equally important is progress in the cold urticaria Phase 3 program. Further positive results there could expand the potential market for barzolvolimab and strengthen its overall value, whereas mixed outcomes might moderate expectations. Readouts from earlier-stage programs, such as the bispecific candidate CDX-622, also deserve attention.
Capital management stays relevant too. Higher R&D spending will keep cash burn elevated as the company moves toward a possible first launch. Management has indicated the balance sheet supports operations through upcoming catalysts, but investors will want to monitor the cash runway and any financing moves. From what I see, this outlook rests on current disclosures and is not a price prediction or investment advice.
My Take on Using Tickeron Tools for Biotech Research
When evaluating clinical-stage names like CLDX, I find it helpful to cross-check patterns and sector comparisons with AI-driven tools. One platform I turn to regularly is Tickeron’s AI Screener, which lets me filter for technical signals, fundamentals, and performance metrics across thousands of stocks and ETFs. It surfaces ideas and comparable setups efficiently and has become a regular part of how I organize my own research process.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CLDX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CLDX turned positive on October 19, 2026. Looking at past instances where CLDX's MACD turned positive, the stock continued to rise in 39 of 46 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CLDX's RSI Indicator exited the oversold zone, 25 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CLDX as a result. In 65 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +3.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLDX advanced for three days, in 205 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
CLDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 57 cases where CLDX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for CLDX entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. CLDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.283) is normal, around the industry mean (3.498). P/E Ratio (-6.867) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. CLDX's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of immunotherapy technologies for the treatment of cancer and other diseases
Industry Biotechnology
Advertisement